Ceruloplasmin Deficiency Drives a Fusiform-Centric Lipid–Myelin Pathology Underlying a Visual Subtype in Autism

Why It Matters

The findings provide a biologically grounded biomarker for a visual subtype of autism and highlight ceruloplasmin‑related metal metabolism as a potential therapeutic target.

Key Takeaways

• Elevated PDFF and altered myelin in fusiform gyrus distinguish ASD visual subtype
• Serum ceruloplasmin and iron are reduced, while lead is increased in ASD‑AVP
• Lipid‑myelin changes mediate the effect of metal biomarkers on brain structure
• Combined imaging markers achieve AUC > 0.9 for detecting ASD‑AVP
• Ceruloplasmin rise over 2 years links to lower fusiform lipid and visual scores

Pulse Analysis

The discovery of a fusiform‑centric lipid‑myelin axis reshapes our understanding of sensory processing deficits in autism. While prior work linked visual anomalies to functional MRI patterns, this study leverages quantitative Dixon PDFF and synthetic MRI to map lipid accumulation and myelin density across the whole brain. The convergence of elevated fat fraction and abnormal myelin specifically in the fusiform gyrus—a region critical for facial recognition—offers a mechanistic explanation for the heightened visual hypersensitivity observed in the ASD‑AVP subgroup. By integrating peripheral metal biomarkers, the research connects systemic oxidative stress to localized neuroanatomical changes, underscoring the role of ceruloplasmin and iron in maintaining myelin integrity.

From a clinical perspective, the combined imaging signature achieves diagnostic performance comparable to invasive biomarker panels, with an area under the curve exceeding 0.9 for distinguishing ASD‑AVP from neurotypical peers. This level of accuracy suggests that non‑invasive MRI protocols could soon serve as screening tools to identify children who may benefit from targeted interventions. Moreover, the mediation analysis reveals that correcting ceruloplasmin deficiency could modulate lipid metabolism, potentially normalizing myelin structure and alleviating visual symptoms. Such insights pave the way for precision medicine approaches that address the metabolic underpinnings of autism subtypes rather than relying solely on behavioral therapies.

The translational relevance extends beyond human cohorts; parallel histological findings in BTBR mouse models validate the fusiform‑centric pathology and demonstrate its reproducibility across species. Longitudinal data, albeit limited, hint at the plasticity of this biomarker axis—children who exhibited increased ceruloplasmin over two years showed reduced fusiform lipid content and improved sensory scores. Future research should expand longitudinal cohorts, explore therapeutic agents that boost ceruloplasmin activity, and assess whether early metabolic correction can alter developmental trajectories. As the field moves toward biologically informed subtyping, this study offers a concrete framework for integrating neuroimaging, peripheral biomarkers, and animal models to drive next‑generation autism care.